Pramlintide

What it is

Pramlintide is a synthetic 37-amino-acid analog of human amylin, supplied in Symlin as the acetate salt. Three proline substitutions separate it from human amylin. Symlin and SymlinPen are products; “amylin analog” is a class, not an exact ingredient.

The approved record was for a sterile subcutaneous pramlintide acetate product. Pramlintide is not endogenous amylin and is not interchangeable with cagrilintide, eloralintide, petrelintide, or another amylin-pathway product. An ingredient or class name does not establish formulation, concentration, device, excipients, sterility, stability, storage history, or approval.

Why people care

Interest in pramlintide has returned with newer amylin and amylin-combination programs. Its record is useful because it separates an approved adjunctive diabetes use, a boxed hypoglycemia warning with insulin, discontinued product marketing, and small older obesity trials that never became a general weight-management approval.

What humans actually show

Pramlintide is a synthetic analog of human amylin. Symlin was FDA approved as an adjunct for defined people with type 1 or type 2 diabetes using mealtime insulin, but the current openFDA exact-substance record lists every Symlin product as Discontinued. The approval was not for general obesity treatment, and pramlintide is not interchangeable with endogenous amylin or newer amylin-pathway products.

• approved label — People with type 1 or type 2 diabetes using mealtime insulin and not at desired glycemic control despite optimized insulin therapy; Route: Subcutaneous Symlin administered as a separate injection from insulin; Outcome: Glycemic control in randomized controlled clinical programs: The label summarizes controlled trials supporting adjunctive use with mealtime insulin and records reductions in glycated hemoglobin and postprandial glucose in defined populations. The seam: The approved use required mealtime insulin and careful patient selection; The product has a boxed warning for severe hypoglycemia with insulin; The approval was not for general obesity treatment; The current openFDA product records are discontinued.
• randomized human — 651 adults with type 1 diabetes using insulin; Route: Mealtime subcutaneous pramlintide or placebo added to insulin for 52 weeks; Outcome: Glycated hemoglobin, body weight, insulin use, and safety: Two pramlintide groups had greater glycated-hemoglobin reductions than placebo and small mean weight decreases while placebo participants gained weight. Transient mild-to-moderate nausea was the most common adverse event. The seam: The participants had type 1 diabetes and used insulin; The glycemic and weight changes were modest trial averages; The result does not support obesity treatment without diabetes; The historical trial does not establish current product availability.
• randomized human — 212 adults with type 2 diabetes suboptimally controlled with basal insulin, with or without oral antihyperglycemic medicines; Route: Subcutaneous pramlintide or placebo added for 16 weeks; Outcome: Composite glycemic-control endpoint, glycated hemoglobin, postprandial glucose, body weight, and hypoglycemia: More pramlintide participants met the composite endpoint; glycated hemoglobin and postprandial glucose improved more and mean weight decreased compared with placebo. The seam: Short trial; The study used basal insulin and does not by itself expand the approved mealtime-insulin indication; The result does not establish a general obesity indication; Trial monitoring does not remove the label's hypoglycemia warning.
• randomized human — 204 adults with obesity, with or without type 2 diabetes, who were not using insulin; Route: Subcutaneous pramlintide or placebo for 16 weeks without a concurrent lifestyle intervention; Outcome: Body weight, waist circumference, tolerability, and safety: Among participants completing treatment, the reported placebo-corrected mean body-weight reduction was 3.7%; nausea was the most common adverse event. The seam: Phase 2 dose-escalation study with 16-week follow-up; The analysis highlighted completers and had substantial withdrawals in both groups; The study used amounts outside the labeled diabetes program; The study did not produce an FDA obesity indication.

Mechanistic and nonhuman evidence

• mechanistic — Labeled pharmacology record using nonclinical and human studies; Route: Subcutaneous labeled product; Outcome: Gastric emptying, postprandial glucagon, postprandial glucose, satiety, and food intake: The label describes slowed gastric emptying, suppression of postprandial glucagon, reduced postprandial glucose, and modulation of satiety and food intake. The seam: Mechanism and short-term food-intake effects do not establish an obesity indication; Slowed gastric emptying creates contraindication and oral-medicine interaction boundaries; Mechanistic similarity does not make different amylin analogs interchangeable.
• animal — Mouse and rat carcinogenicity and rat fertility studies summarized in the label; Route: Pramlintide exposure in animals; Outcome: Tumors, mutagenicity, fertility, and maternal toxicity: The label reports no drug-induced tumors in the cited mouse and rat studies and no significant fertility effect in rats, while the highest tested fertility-study exposure produced maternal toxicity and dystocia. The seam: Animal findings do not establish human long-term safety; Absence of tumors in these studies is not proof of no human risk; The studies do not establish efficacy.

FDA and U.S. status

Symlin was FDA approved as an adjunctive treatment for patients with type 1 or type 2 diabetes who use mealtime insulin and failed to achieve desired glucose control despite optimal insulin therapy. The latest FDA label located is revised December 2019. The openFDA exact-substance record, last updated July 28, 2026, lists all NDA021332 Symlin products with Discontinued marketing status. This does not establish approval withdrawal, remaining inventory, foreign availability, or approval for obesity.

Risks and warning limits

• approved label: The Symlin label carries a boxed warning that use with insulin increases the risk of severe hypoglycemia, particularly in type 1 diabetes, and that serious injury can occur if an episode happens during a high-risk activity.
• approved label: The label contraindicates Symlin in people with hypoglycemia unawareness, confirmed gastroparesis, or serious hypersensitivity to the product. It requires careful patient selection and states that pramlintide and insulin must be separate injections and never mixed.
• human trial: The most common labeled adverse reactions are nausea, vomiting, anorexia, and headache; injection-site reactions and postmarketing hypersensitivity are also recorded.

What remains unknown

• Current practical availability and remaining inventory cannot be established from the discontinued openFDA marketing-status field alone.
• The cited obesity studies do not establish long-term obesity outcomes or an FDA-approved weight-management indication.
• The safety and effectiveness of combining pramlintide with newer amylin analogs or GLP-1 products are not established by the cited Symlin record.
• The identity, potency, sterility, stability, and excipient profile of a compounded or unidentified pramlintide product cannot be inferred from the ingredient name.

Product identity and quality limits

• Pramlintide is a defined synthetic amylin analog and is not identical to endogenous human amylin.
• Pramlintide cannot be treated as interchangeable with cagrilintide, eloralintide, petrelintide, or another amylin-pathway product merely because they share a pathway or class description.
• Compounded drugs are not FDA approved, and the discontinued Symlin label does not validate another formulation or product.

What has been studied together

• Pramlintide with mealtime insulin — coadministration studied: Adjunctive use with mealtime insulin is the historical approved use and was studied in controlled trials. The label carries a boxed severe-hypoglycemia warning and states that the two products must be administered as separate injections and never mixed. This is not general compatibility clearance.
• Pramlintide with oral medicines or medicines that alter gastrointestinal motility — known label boundary: Because pramlintide slows gastric emptying, the label records delayed absorption concerns for oral medicines and says it is not recommended with other medicines that alter gastrointestinal motility. The record is not a universal prediction for every medicine.

What people are hearing

These are claims this profile checks, not established conclusions.

• Claim under review: “Because pramlintide produced weight loss in some human studies, Symlin was FDA approved for obesity.”
• Claim under review: “An FDA approval record means Symlin is still actively marketed in the United States.”
• Claim under review: “Pramlintide can be treated as interchangeable with human amylin or any newer amylin analog.”

Questions readers raise

• No reproducible community sample was collected for this profile.

The community-signal layer is not efficacy or safety evidence. Its current limits are:

• No reproducible community sample has been collected for this profile.
• Self-reports would be subject to selection and reporting bias.
• The identity of a reported amylin-pathway product could not be assumed.
• Concurrent insulin, other medicines, health conditions, diet, and behavior could confound an anecdote.
• Reported outcomes could not be independently verified.
• Anecdotes cannot establish efficacy, safety, approval, availability, product identity, or interaction compatibility.

What would change this answer

• A new FDA marketing-status record, approval action, withdrawal action, or revised label would change the exact United States product boundary.
• Large long-term randomized trials in a clearly defined obesity population with patient-important outcomes and an FDA review action would be required to change the obesity-approval boundary.
• Direct combination trials and product-specific evidence would be required before drawing conclusions about pramlintide with newer amylin or GLP-1 products.

Sources and records

• WADA — 2026 Prohibited List

• SYMLIN (pramlintide acetate) prescribing information, revised December 2019 — U.S. Food and Drug Administration
• Drugs@FDA API exact active-ingredient search for pramlintide — U.S. Food and Drug Administration
• Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration
• ClinicalTrials.gov intervention search for pramlintide — ClinicalTrials.gov
• PubMed search for pramlintide in human records — National Library of Medicine
• Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial — PubMed
• Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin — PubMed
• Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study — PubMed